论文部分内容阅读
自中国医科分院血液研究所等单位发现中药青黛的一种成分——靛玉红对慢性粒细胞性血白病(下称慢粒)有明显疗效以来,我们最近也使用本药治疗一些慢粒患者,确有较好疗效,现就观察结果报导如下。对象和方法自1978年9月到1979年3月底,我们用靛玉红治疗11例慢粒患者(见下表),其中男性6例,女性5例,年龄17到48岁。治前病程4至29个月。所有病例均经临床、骨髓及血象检查确定诊断。全部病例均单独使用靛玉红治疗。靛玉红片剂系四川省中药究研所供给,每片含50毫克,每日剂量150—200毫克,分三至四次口服,连续用药,用药后及时观
Since the Chinese Medical Branch Blood Institute and other units found that a component of Chinese medicine indigo, indirubin has a significant effect on chronic myelogenous leukemia (hereinafter referred to as slow-grain), we have recently used this drug to treat some cicada Patients, there is indeed a good effect, the observations are reported as follows. Subjects and Methods From September 1978 to the end of March 1979, we treated 11 patients with chronic granulocytes (see table below) with indirubin, of which 6 were males and 5 females, aged 17 to 48 years. Pre-treatment course of 4 to 29 months. All cases were diagnosed by clinical, bone marrow and blood tests. All cases were treated with indirubin alone. Indirubin tablets Sichuan Institute of Traditional Chinese Medicine supply, each containing 50 mg daily dose of 150-200 mg, three to four times orally, continuous medication, medication and timely view